Szeto-Schiller 31 eases acute lung injury in neonatal mice with acute respiratory distress syndrome by mediating TXNIP expression and NLRP3 inflammasome activation.

Zhu M, Song L, Wei Y, Hong F, Lu Y, Ji J, Yan Y

Translational pediatrics28 Jul 2025Cited by 2 (Europe PMC)

PMID40800174PMCIDPMC12336897DOI10.21037/tp-2025-165PepBankPUB-40800174

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study13

12 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In neonatal mice with ARDS, SS‑31 treatment ameliorated histopathological changes in the lungs.
In plain wordsIn newborn mice with ARDS, SS‑31 improved lung tissue damage.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseLung histopathological changes
Study
mousen: not reported in source
neonatal ARDS mice
Outcome group
Lung injury and fibrosis · Respiratory
Studied dose
Dose not stated
Source sentences
Summary
Consistently, SS-31 treatment ameliorated histopathological changes and oedema in the lungs of neonatal ARDS mice, accompanied by improved alveolar capillary barrier integrity as well as reduced OxS, inflammation, and apoptosis.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of SS-31 on oxidative stress (OxS) injury, inflammation, apoptosis, and vascular permeability in lipopolysaccharide (LPS)-induced human lung microvascular epithelial cells (HLMVECs) and ARDS mouse models were investigated
Report a problemFND-4080017405
02AnimalAnimal study (in vivo)Efficacy outcome
In neonatal mice with ARDS, SS‑31 treatment ameliorated oedema in the lungs.
In plain wordsIn newborn mice with ARDS, SS‑31 reduced lung swelling.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseLung oedema
Study
mousen: not reported in source
neonatal ARDS mice
Outcome group
Lung injury and fibrosis · Respiratory
Studied dose
Dose not stated
Source sentences
Summary
Consistently, SS-31 treatment ameliorated histopathological changes and oedema in the lungs of neonatal ARDS mice, accompanied by improved alveolar capillary barrier integrity as well as reduced OxS, inflammation, and apoptosis.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of SS-31 on oxidative stress (OxS) injury, inflammation, apoptosis, and vascular permeability in lipopolysaccharide (LPS)-induced human lung microvascular epithelial cells (HLMVECs) and ARDS mouse models were investigated
Report a problemFND-4080017406
03AnimalAnimal study (in vivo)Efficacy outcome
In neonatal mice with ARDS, SS‑31 treatment improved alveolar capillary barrier integrity.
In plain wordsIn newborn mice with ARDS, SS‑31 improved the lung barrier between air sacs and blood vessels.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseAlveolar capillary barrier integrity
Study
mousen: not reported in source
neonatal ARDS mice
Outcome group
Vascular function · Respiratory
Studied dose
Dose not stated
Source sentences
Summary
Consistently, SS-31 treatment ameliorated histopathological changes and oedema in the lungs of neonatal ARDS mice, accompanied by improved alveolar capillary barrier integrity as well as reduced OxS, inflammation, and apoptosis.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of SS-31 on oxidative stress (OxS) injury, inflammation, apoptosis, and vascular permeability in lipopolysaccharide (LPS)-induced human lung microvascular epithelial cells (HLMVECs) and ARDS mouse models were investigated
Report a problemFND-4080017407
04AnimalAnimal study (in vivo)Efficacy outcome
In neonatal mice with ARDS, SS‑31 treatment reduced oxidative stress.
In plain wordsIn newborn mice with ARDS, SS‑31 lowered oxidative stress.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseOxidative stress in lungs
Study
mousen: not reported in source
neonatal ARDS mice
Outcome group
Oxidative stress · Respiratory
Studied dose
Dose not stated
Source sentences
Summary
Consistently, SS-31 treatment ameliorated histopathological changes and oedema in the lungs of neonatal ARDS mice, accompanied by improved alveolar capillary barrier integrity as well as reduced OxS, inflammation, and apoptosis.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of SS-31 on oxidative stress (OxS) injury, inflammation, apoptosis, and vascular permeability in lipopolysaccharide (LPS)-induced human lung microvascular epithelial cells (HLMVECs) and ARDS mouse models were investigated
Report a problemFND-4080017408
05AnimalAnimal study (in vivo)Efficacy outcome
In neonatal mice with ARDS, SS‑31 treatment reduced inflammation.
In plain wordsIn newborn mice with ARDS, SS‑31 lowered inflammation.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseInflammation in lungs
Study
mousen: not reported in source
neonatal ARDS mice
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Consistently, SS-31 treatment ameliorated histopathological changes and oedema in the lungs of neonatal ARDS mice, accompanied by improved alveolar capillary barrier integrity as well as reduced OxS, inflammation, and apoptosis.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of SS-31 on oxidative stress (OxS) injury, inflammation, apoptosis, and vascular permeability in lipopolysaccharide (LPS)-induced human lung microvascular epithelial cells (HLMVECs) and ARDS mouse models were investigated
Report a problemFND-4080017409
06AnimalAnimal study (in vivo)Efficacy outcome
In neonatal mice with ARDS, SS‑31 treatment reduced apoptosis.
In plain wordsIn newborn mice with ARDS, SS‑31 lowered cell death.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseApoptosis in lungs
Study
mousen: not reported in source
neonatal ARDS mice
Outcome group
Cell viability and death · Respiratory
Studied dose
Dose not stated
Source sentences
Summary
Consistently, SS-31 treatment ameliorated histopathological changes and oedema in the lungs of neonatal ARDS mice, accompanied by improved alveolar capillary barrier integrity as well as reduced OxS, inflammation, and apoptosis.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of SS-31 on oxidative stress (OxS) injury, inflammation, apoptosis, and vascular permeability in lipopolysaccharide (LPS)-induced human lung microvascular epithelial cells (HLMVECs) and ARDS mouse models were investigated
Report a problemFND-4080017410
07AnimalAnimal study (in vivo)Mechanism
In ARDS animal models, SS‑31 treatment repressed TXNIP and NLRP3 protein levels.
In plain wordsIn mice with ARDS, SS‑31 lowered the TXNIP and NLRP3 proteins.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseTXNIP and NLRP3 protein levels in ARDS animals
Study
mousen: not reported in source
neonatal ARDS mice
Outcome group
Receptor activity and mechanism · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Interestingly, SS-31 treatment repressed TXNIP and NLRP3 protein levels in ARDS cells and animal models.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of SS-31 on oxidative stress (OxS) injury, inflammation, apoptosis, and vascular permeability in lipopolysaccharide (LPS)-induced human lung microvascular epithelial cells (HLMVECs) and ARDS mouse models were investigated
Report a problemFND-4080017412
08LabIn vitro (cells)Efficacy outcome
In LPS-induced human lung microvascular cells, SS‑31 mitigated oxidative stress.
In plain wordsIn lab tests on human lung cells, SS‑31 reduced oxidative stress caused by LPS.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseOxidative stress injury in HLMVECs
Study
humann: not reported in source
LPS-induced HLMVECs
Outcome group
Oxidative stress · Respiratory
Studied dose
Dose not stated
Source sentences
Summary
SS-31 treatment mitigated LPS-induced OxS, apoptosis, vascular permeability, and inflammatory response in HLMVECs.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of SS-31 on oxidative stress (OxS) injury, inflammation, apoptosis, and vascular permeability in lipopolysaccharide (LPS)-induced human lung microvascular epithelial cells (HLMVECs) and ARDS mouse models were investigated
Report a problemFND-4080017401
09LabIn vitro (cells)Efficacy outcome
In LPS-induced human lung microvascular cells, SS‑31 mitigated apoptosis.
In plain wordsIn lab tests on human lung cells, SS‑31 reduced cell death caused by LPS.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseApoptosis in HLMVECs
Study
humann: not reported in source
LPS-induced HLMVECs
Outcome group
Cell viability and death · Respiratory
Studied dose
Dose not stated
Source sentences
Summary
SS-31 treatment mitigated LPS-induced OxS, apoptosis, vascular permeability, and inflammatory response in HLMVECs.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of SS-31 on oxidative stress (OxS) injury, inflammation, apoptosis, and vascular permeability in lipopolysaccharide (LPS)-induced human lung microvascular epithelial cells (HLMVECs) and ARDS mouse models were investigated
Report a problemFND-4080017402
10LabIn vitro (cells)Efficacy outcome
In LPS-induced human lung microvascular cells, SS‑31 mitigated vascular permeability.
In plain wordsIn lab tests on human lung cells, SS‑31 reduced leakiness caused by LPS.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseVascular permeability in HLMVECs
Study
humann: not reported in source
LPS-induced HLMVECs
Outcome group
Vascular function · Respiratory
Studied dose
Dose not stated
Source sentences
Summary
SS-31 treatment mitigated LPS-induced OxS, apoptosis, vascular permeability, and inflammatory response in HLMVECs.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of SS-31 on oxidative stress (OxS) injury, inflammation, apoptosis, and vascular permeability in lipopolysaccharide (LPS)-induced human lung microvascular epithelial cells (HLMVECs) and ARDS mouse models were investigated
Report a problemFND-4080017403
11LabIn vitro (cells)Efficacy outcome
In LPS-induced human lung microvascular cells, SS‑31 mitigated the inflammatory response.
In plain wordsIn lab tests on human lung cells, SS‑31 reduced the inflammatory response caused by LPS.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseInflammatory response in HLMVECs
Study
humann: not reported in source
LPS-induced HLMVECs
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
SS-31 treatment mitigated LPS-induced OxS, apoptosis, vascular permeability, and inflammatory response in HLMVECs.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of SS-31 on oxidative stress (OxS) injury, inflammation, apoptosis, and vascular permeability in lipopolysaccharide (LPS)-induced human lung microvascular epithelial cells (HLMVECs) and ARDS mouse models were investigated
Report a problemFND-4080017404
12LabIn vitro (cells)Mechanism
In ARDS cell models, SS‑31 treatment repressed TXNIP and NLRP3 protein levels.
In plain wordsIn lab tests on ARDS cells, SS‑31 lowered the TXNIP and NLRP3 proteins.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseTXNIP and NLRP3 protein levels in ARDS cells
Study
humann: not reported in source
ARDS cells
Outcome group
Receptor activity and mechanism · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Interestingly, SS-31 treatment repressed TXNIP and NLRP3 protein levels in ARDS cells and animal models.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of SS-31 on oxidative stress (OxS) injury, inflammation, apoptosis, and vascular permeability in lipopolysaccharide (LPS)-induced human lung microvascular epithelial cells (HLMVECs) and ARDS mouse models were investigated
Report a problemFND-4080017411

Studies that did not test the peptide alone1

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

13Computer modelNot a test of Elamipretide (SS-31) aloneIn silicoMechanism
A search of the STITCH chemical-interaction database indicated that SS‑31 works by mediating TXNIP expression.
In plain wordsIn a computer database search, SS‑31 was linked to the TXNIP protein. This is a prediction, not a test in living cells.
Peptide
Elamipretide (SS-31)
Outcome
Not applicableSS-31 link to TXNIP expression in a chemical-interaction database
Study
n: not reported in source
STITCH database search
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Using the Search Tool for Interactions of Chemicals (STITCH) database, SS-31 was found to work via mediating TXNIP expression.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4080017413

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.